INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines

ARS Pharmaceuticals faces a newly filed securities class action alleging fraud and unlawful business practices. The backdrop is ARS’s June 24 disclosure that it did not receive expanded CVS Caremark insurance coverage for neffy by July 1, with a decision deferred to January 2027, and ARS shares subsequently fell $2.52 (23.91%) to $8.02 on June 25, 2026. While the filing is legal in nature, it reinforces investor concern around neffy coverage/timeline risk and potential litigation over the company’s disclosures.

Analysis

This is less about the lawsuit itself than about the company’s already-fragile commercialization narrative getting another credibility hit. In small-cap biotech, litigation headlines rarely move the terminal value by themselves; they matter because they keep the stock in a “show-me” state, raising the cost of capital and making any secondary or partnership financing more dilutive. The immediate loser is SPRY’s equity multiple: payer uncertainty plus legal noise compresses valuation before the market even gets to the real question of whether adoption can reaccelerate.

The competitive read-through is more interesting. Any delay in broad coverage effectively extends the life of legacy injectable epinephrine products and their channel economics, because formulary inertia matters more than product differentiation in rescue meds. That is a small but real tailwind for incumbents and distributors that are not relying on a single new-category launch to justify growth; it also slows the “category expansion” thesis for pharmacies, schools, and employers that would otherwise be early adopters if reimbursement were clean.

The key catalyst window is January 2027, not the class action timeline. Over the next 1-3 months, expect the stock to trade on every incremental payer signal, prescription trend, and cash burn disclosure rather than on legal merits. The contrarian risk is that the market may be overestimating litigation damage and underestimating how much of the equity value already reflects the coverage miss; if management shows robust cash-fill momentum without expanded coverage, the headline overhang can fade quickly.

For falsification, watch for a reinstated or expanded CVS decision, a meaningful acceleration in net prescriptions, or evidence that gross-to-net is stabilizing despite limited coverage. If those do not appear by the next update cycle, the stock remains vulnerable to a lower-for-longer multiple, especially if burn rate forces financing before the January decision.

Key Decisions for Investors

• Avoid initiating new long SPRY exposure until there is either expanded CVS coverage or at least two monthly prescription prints showing acceleration without payer support; near-term risk/reward remains skewed negative.
• If liquidity allows, use any relief rally in SPRY to build a small short or buy put spreads with a 1-3 month tenor; thesis is multiple compression from ongoing payer uncertainty rather than litigation damages.
• Watch VTRS and other legacy epinephrine incumbents as a relative winner pair trade versus SPRY into the January 2027 coverage decision; long incumbent / short SPRY can express formulary inertia with less binary product risk.
• Set a falsifier alert on SPRY if management reports materially improving cash-prescriptions or a payer win before year-end; that would weaken the short thesis and argue for covering risk quickly.